Exhibit 99.1 Cyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE - New Clinical Data to be Presented at ASCO Annual Meeting Highlighting Potential Precision Medicine Strategy with Oral Fadraciclib - - First Patients Enrolled in Oral Fadraciclib Phase 2 Proof of Concept Study - - Balance Sheet Bolstered with $8.0 million Private Placement Priced At-The-Market Under Nasdaq Rules - - Management to Host Conference Call at 4:30 pm EDT Today ...